Quick search
Advanced search in
Field to searchTerm
Add rule
Download Results
7 research outcomes, page 1 of 1
  • publication . Article . 2020
    Open Access
    Authors:
    S. Yu. Martsevich;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat

    The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors c...

    Add to ORCIDorcid
  • This review analyzes existing approaches to the treatment of COVID-19 patients with antimalarial drugs from the standpoint of rational pharmacotherapy. Particular attention is paid to drug interactions and side effects of co-administration of chloroquine/hydroxychloroqu...

    Add to ORCIDorcid
  • publication . Article . 2021
    Open Access English
    Authors:
    V. I. Podzolkov; A. E. Bragina; A. I. Tarzimanova; L. V. Vasil'eva; E. P. Batrakova; N. V. Lobova; E. E. Bykova; M. M. Khachuroeva;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniya

    The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase, but also persisting symptoms 4 weeks after the onset of the disease. A review of international studies on the prevalence and diversity of the manifestati...

    Add to ORCIDorcid
  • publication . Article . 2021
    Open Access English
    Authors:
    V. I. Podzolkov; A. I. Tarzimanova;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniya

    At the end of 2020, a new term “post-COVID-19 syndrome” appeared in the medical community. The prevalence of this syndrome reaches more than 30% among patients who have had COVID-19, and its duration can vary from 12 weeks to 6 months. One of the most severe consequence...

    Add to ORCIDorcid
  • publication . Article . 2020
    Open Access
    Authors:
    O. V. Blagova; N. V. Varionchik; M. M. Beraia; V. A. Zaidenov; E. A. Kogan; N. D. Sarkisova; Nedostup Av;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat

    Patients with chronic myocarditis have a high risk of an unfavorable course of the novel coronavirus disease (COVID-19) due to the ability of the SARS-Cov-2 virus to independently cause acute myocarditis, to have a direct and cytokine-mediated cytopathic effect on the m...

    Add to ORCIDorcid
  • publication . Article . 2020
    Open Access
    Authors:
    O. V. Blagova; N. V. Varionchik; M. M. Beraia; V. A. Zaidenov; E. A. Kogan; N. D. Sarkisova; Nedostup Av;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat

    Chronic infectious-immune myocarditis of severe course can potentially be considered as a factor that aggravates the course of new coronavirus disease (COVID-19) and increases the risk of adverse outcomes. The interaction of chronic myocarditis and COVID-19 during long-...

    Add to ORCIDorcid
  • publication . Article . 2021
    Open Access
    Authors:
    S. Y. Martsevich; Y. V. Lukina; E. D. Zharkova; N. P. Kutishenko;
    Persistent Identifiers
    Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat

    The new coronavirus infection (COVID-19) pandemic and the subsequent quarantine measures, particularly home isolation of the population, could have seriously affected the quality of pharmacotherapy and adherence to it by patients with chronic non-communicable diseases.A...

    Add to ORCIDorcid
7 research outcomes, page 1 of 1